Lenalidomide Grindeks (Lenalidomide)

Lenalidomide is used in the management of malignant blood disorders by targeting abnormal plasma cells and related pathways.

• Multiple myeloma: reduces disease progression and improves survival in patients with relapsed or refractory disease.
• Myelodysplastic syndromes: decreases transfusion dependence and modifies disease course in patients with deletion 5q cytogenetic abnormality.
• Mantle cell lymphoma: contributes to tumor control when combined with other chemotherapeutic agents.

• Lenalidomide binds to the cereblon component of the CRL4 E3 ubiquitin ligase complex, promoting ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos. This leads to altered cytokine production, enhanced T‑cell and NK‑cell mediated immunity, inhibition of angiogenesis, and direct anti‑myeloma activity through apoptosis of malignant cells.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Fatigue: persistent tiredness affecting daily activities.
• Diarrhea: loose stools that may require fluid replacement.
• Rash: mild skin eruptions that are usually self‑limiting.
• Constipation: reduced bowel movements causing discomfort.
• Nausea: feeling of sickness that may affect appetite.
• Peripheral edema: swelling of extremities.

Serious or Rare Side Effects

• Thromboembolic events: deep vein thrombosis or pulmonary embolism requiring immediate medical attention.
• Severe neutropenia: markedly low neutrophil count increasing infection risk.
• Hepatotoxicity: elevated liver enzymes indicating liver injury.
• Secondary malignancies: emergence of new cancers unrelated to the primary disease.
• Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Cardiac arrhythmias: irregular heart rhythms that may be life‑threatening.

Before initiating therapy, clinicians should assess patient history and monitor key parameters.

• Pregnancy risk: contraindicated in pregnancy (Category X); ensure effective contraception for women of childbearing potential.
• Thrombo‑risk assessment: evaluate need for prophylactic anticoagulation in patients with additional risk factors.
• Renal function: adjust monitoring in patients with impaired kidney function.
• Hepatic function: monitor liver enzymes regularly during treatment.
• Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct light.

Lenalidomide can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers: may reduce plasma concentrations of lenalidomide.
• Anticoagulants (e.g., warfarin): increased risk of bleeding when combined.

Moderate Interactions (Monitor Closely)

• Immunosuppressants (e.g., cyclosporine): may enhance hematologic toxicity.
• CYP3A4 inhibitors: potential modest increase in lenalidomide exposure.
• Vaccines: live attenuated vaccines should be avoided during therapy.
• Herbal supplements (e.g., St. John’s wort): could affect drug metabolism.
• NSAIDs: may increase risk of renal impairment when used together.